Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs

Abstract

Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas and is ultimately due to antibodies interacting with the TSH receptor on thyroid follicular cells [TSH-receptor antibody (TRAb)]. Antithyroid drugs (ATDs) belonging to the family of thionamides are the first-line treatment in Europe. ATD treatment is commonly continued for 18–24 months. Its major limitation is the high rate of relapses after drug withdrawal. Factors particularly bound to subsequent relapses are the large thyroid volume, smoking habit, persistence of TRAb in the circulation at the end of treatment, and the post-partum period. Under these conditions, consideration should be given to a definitive therapy for hyperthyroidism (radioiodine treatment, thyroidectomy), particularly if the patient is at risk of cardiovascular complications that might be exacerbated by persistence or recurrence of hyperthyroidism.

Key words

Graves’ hyperthyroidism - Graves’ orbitopathy - thionamides - methimazole - TSH-receptor antibody - smoking - goiter

Publikationsverlauf

Eingereicht: 07. April 2015

Angenommen: 28. Mai 2015

Artikel online veröffentlicht:
21. Juli 2015

• References

• 1 Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9: 724-734
• 2 Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37: 691-700
• 3 Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726-738
• 4 Johnson KTM, Wiesweg B, Schott M, Ehlers M, Müller M, Minich WB, Nagayama Y, Gulbins E, Eckstein AK, Berchner-Pfannschmidt U. Examination of orbital tissues in murine models of Graves’ disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Horm Metab Res 2013; 45: 401-407
• 5 Wiesweg B, Johnson KTM, Eckstein AK, Berchner-Pfannschmidt U. Current insights into animal models of Graves’ disease and orbitopathy. Horm Metab Res 2013; 45: 549-555
• 6 Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 2013; 36: 444-449
• 7 Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 2014; 37: 1041-1048
• 8 Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 2014; Dec 8
• 9 Burch HB, Burman KD, Cooper DS. A survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012; 97: 4549-4558
• 10 Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug therapy. Thyroid 1997; 3: 369-375
• 11 Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SCL, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042
• 12 Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Mirad MH, Bahn RS. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98: 3671-3677
• 13 Ohye H, Mainagawa A, Yoshimura Noh J, Mukasa K, Kunji Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito Ko, Ito Ku. Antithyroid drug treatment for Graves’ disease in children: a long-term retrospective study at a single institution. Thyroid 2014; 24: 200-207
• 14 Mohlin E, Filipsson Nystrom H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol 2014; 170: 419-427
• 15 Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev 2010;
• 16 Brent GA. Clinical Practice: Graves’ disease. N Engl J Med 2008; 358: 2594-2605
• 17 Aizawa T, Ishihara M, Hashizume K, Takasu N, Yamada T. Age-related changes of thyroid function and immunologic abnormalities in patients with hyperthyroidism due to Graves’ disease. J Am Geriatr Soc 1989; 37: 944-948
• 18 Winsa B, Dahlberg PA, Jansson R, Agren H, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease. Acta Endocrinol (Copenh) 1990; 122: 622-628
• 19 Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002; 147: 583-589
• 20 Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, Panagiotou A, Kita M. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 2013; 44: 448-453
• 21 Wang P-W, Chen I-Y, Juo S-HH, His E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J 2012; 1: 251-258
• 22 Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H. and the Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs . Is there a a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. Clin Endocrinol (Oxf) 1998; 49: 451-457
• 23 Kaguelidou F, Alberti C, Castanet M, Guitteny M-A, Czernichow P, Léger J. for the French Childhood Graves’ Disease Study Group . Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93: 3817-3826
• 24 Carlé A, Bulow Pedersen I, Knudsen N, Perrild H, Ovesen L, Banke Rasmussen L, Laurberg P. Epidemiology of subtypes of hyperthyroidism in Denmark: a polulation-based study. Eur J Endocrinol 2011; 164: 801-809
• 25 Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Agabiti Rosei E. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocrine J 2007; 54: 713-720
• 26 Dauksenie D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves’ disease outcome. Medicina (Kaunas) 2013; 49: 427-434
• 27 Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol (Copenh) 1986; 111: 39-43
• 28 Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. and the French Childhood Graves’ Disease Study Group . Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012; 97: 110-119
• 29 Choo YK, Yoo WS, Kim DW, Chung H-K. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves’ disease. Thyroid 2010; 20: 949-954
• 30 Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 2010; 162: 438-446
• 31 Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generation of methods. Systematic review and meta-analysis. Autoimmunity Rev 2012; 12: 107-113
• 32 Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, Konig J, Bossowska A, Ziora K, Hale A, Smith J, Pitz S, Kanitz M, Kahaly GJ. Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves’ disease – a multicenter study. J Clin Endocrinol Metab 2014; 99: 1648-1655
• 33 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75
• 34 Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?. Eur J Endocrinol 2006; 155: 783-786
• 35 Stefanic M, Karner I. Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves’ disease in Croatian patients. J Endocrinol Invest 2014; 37: 71-77
• 36 Feldt-Rassmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 1994; 78: 98-102
• 37 Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013; 98: 2247-2255
• 38 Tanda ML, Piantanida E, Liparulo L, Veronesi G, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 98: 1443-1449
• 39 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997; 47: 9-14
• 40 Rebelo Pinto E, dos S, Lopes FPPL, de Souza SAL, da Fonseca LMB, Visman M, Gutfilen B, de dos Santos Teixeira PF. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in Graves’ ophthalmopathy patients with different Clinical Activity Score. Horm Metab Res 2013; 45: 765-768
• 41 Eckstein AK, Lax H, Losch C, Glowacka D, Plicht M, Mann K, Esser J, Morgenthaler NG. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 2007; 67: 607-612
• 42 Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Kerjbjerg A, Bulow Pedersen I, Linding Andersen S. Association between TSH-receptor autoimmunity, hyperthyroidism, goiter, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves’ disease study. J Thyroid Res 2014; Article ID 165487
• 43 Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489-498
• 44 Vaidya B, Wright A, Shuttleworth J, Donohe M, Warren R, Brooke A, Gericke CA, Ukoumunne OC. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves’ disease: a retrospective observational study. Clin Endocrinol (Oxf) 2014; 81: 610-613
• 45 Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 593-646
• 46 Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs. continuous treatment with low methimazole dose: a retrospective study. J Endocrinol Invest 2008; 31: 866-872
• 47 Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 2011; 21: 279-283
• 48 Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid 2011; 21: 951-956
• 49 Vestergaard P. Smoking and thyroid disorders – a meta-analysis. Eur J Endocrinol 2002; 146: 153-161
• 50 Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf) 2013; 79: 145-151
• 51 Nyirenda MJ, Taylor PN, Stoddart M, Beckett GJ, Toft AD. Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs nonsmokers with Graves’ disease treated with carbimazole. JAMA 2009; 301: 162-164
• 52 Hou X, Li Y, Li I, Wang W, Fan C, Wang H, Zhang H, Shan Z, Teng W. Development of thyroid dysfunction and autoantibodies in Graves’ multiplex families: an eight-year follow-up study in Chinese Han pedigrees. Thyroid 2011; 12: 1353-1358
• 53 Glinoer D, de Nayer P, Bex M. and the Belgian Collaborative Study Group on Graves’ Disease . Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144: 475-483
• 54 Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves’ disease?. J Endocrinol Invest 2002; 25: 152-157
• 55 Aagaard-Tyllery KM, Silver R, Dalton J. Immunology of normal pregnancy. Semin Fetal Neonatal Med 2006; 11: 279-295
• 56 Davies TF. The thyroid immunology of the post-partum period. Thyroid 1999; 9: 675-684
• 57 Amino N, Tada H, Hidaka Y. Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Thyroid 1999; 9: 705-713
• 58 Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Agabiti Rosei E, Chiovato L. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 2008; 93: 3985-3988
• 59 Nagakawa Y, Mori K, Hoshikawa S, Yamamoto M, Ito S, Yoshida K. Postpartum recurrence of Graves’ hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy. Clin Endocrinol (Oxf) 2002; 57: 467-471
• 60 Weetman AP. Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?. Clin Endocrinol (Oxf) 2014; 80: 629-632
• 61 Cossburn M, Pace AA, Jones J, Ali R, Ingram C, Baker K, Hirst C, Zajicek J. Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77: 573-579
• 62 Daniels GH, Vladic A, Brinar V, Zavalishib I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014; 99: 80-89
• 63 Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005; 84: 98-106
• 64 Honda A, Kashiwazaki K, Tsunoda T, Gallant JE, Brown TT. Short communication: CD4 cell count increases during successful treatment of Graves’ disease with methimazole in HIV-affected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 1627-1629